Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2019

Open Access 01-12-2019 | Prostate Cancer | Review

Effects of hyperglycemia on the progression of tumor diseases

Authors: Wenjie Li, Xuehui Zhang, Hui Sang, Ying Zhou, Chunyu Shang, Yongqing Wang, Hong Zhu

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2019

Login to get access

Abstract

Malignant tumors are often multifactorial. Epidemiological studies have shown that hyperglycemia raises the prevalence and mortality of certain malignancies, like breast, liver, bladder, pancreatic, colorectal, endometrial cancers. Hyperglycemia can promote the proliferation, invasion and migration, induce the apoptotic resistance and enhance the chemoresistance of tumor cells. This review focuses on the new findings in the relationship between hyperglycemia and tumor development.
Literature
1.
Scappaticcio L, Maiorino MI, Bellastella G, Giugliano D, Esposito K. Insights into the relationships between diabetes, prediabetes, and cancer. ENDOCRINE. 2017;56:231–9.CrossRef
2.
Pandey A, Forte V, Abdallah M, et al. Diabetes mellitus and the risk of cancer. Minerva Endocrinol. 2011;36:187–209.PubMed
3.
Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009;16:1103–23.CrossRef
4.
Huang Y, Cai X, Qiu M, et al. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia. 2014;57:2261–9.CrossRef
5.
Zhou XH, Qiao Q, Zethelius B, et al. Diabetes, prediabetes and cancer mortality. Diabetologia. 2010;53:1867–76.CrossRef
6.
Popkin BM. Nutrition transition and the global diabetes epidemic. Curr Diab Rep. 2015;15:64.CrossRef
7.
Garg SK, Maurer H, Reed K, Selagamsetty R. Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab. 2014;16:97–110.CrossRef
8.
Dabrowski M, Szymanska-Garbacz E, Miszczyszyn Z, Derezinski T, Czupryniak L. Risk factors for cancer development in type 2 diabetes: a retrospective case-control study. BMC Cancer. 2016;16:785.CrossRef
9.
Tseng CH. Type 2 diabetes mellitus and kidney Cancer risk: a retrospective cohort analysis of the National Health Insurance. PLoS One. 2015;10:e142480.
10.
De Lorenzo MS, Baljinnyam E, Vatner DE, et al. Caloric restriction reduces growth of mammary tumors and metastases. Carcinogenesis. 2011;32:1381–7.CrossRef
11.
Lee C, Longo VD. Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients. Oncogene. 2011;30:3305–16.CrossRef
12.
Seyfried TN, Kiebish MA, Marsh J, et al. Metabolic management of brain cancer. Biochim Biophys Acta. 2011;1807:577–94.CrossRef
13.
14.
Westley RL, May FE. A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors. Int J Endocrinol 2013;2013:632461.CrossRef
15.
Joshi S, Liu M, Turner N. Diabetes and its link with cancer: providing the fuel and spark to launch an aggressive growth regime. Biomed Res Int. 2015;2015:390863.CrossRef
16.
Hou Y, Zhou M, Xie J, et al. High glucose levels promote the proliferation of breast cancer cells through GTPases. Breast Cancer (Dove Med Press). 2017;9:429–36.
17.
Han L, Ma Q, Li J, et al. High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR. PLoS One. 2011;6:e27074.CrossRef
18.
Pothiwala P, Jain SK, Yaturu S. Metabolic syndrome and cancer. Metab Syndr Relat Disord. 2009;7:279–88.CrossRef
19.
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–90.CrossRef
20.
Kalluri R, Weinberg RA. The basics of epithelialmesenchymal transition. Journal of Clinical Investigation2009, 119 (6) :1420–1428.CrossRef
21.
Flores-Lopez LA, Martinez-Hernandez MG, Viedma-Rodriguez R, Diaz-Flores M, Baiza-Gutman LA. High glucose and insulin enhance uPA expression, ROS formation and invasiveness in breast cancer-derived cells. Cell Oncol (Dordr). 2016;39:365–78.CrossRef
22.
Li X, Li J, Cai Y, et al. Hyperglycaemia-induced miR-301a promotes cell proliferation by repressing p21 and Smad4 in prostate cancer. Cancer Lett. 2018;418:211–20.CrossRef
23.
Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9:400–14.CrossRef
24.
Ding Z, Wu CJ, Chu GC, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011;470:269–73.CrossRef
25.
Zhou P, Jiang W, Wu L, et al. miR-301a is a candidate oncogene that targets the homeobox gene Gax in human hepatocellular carcinoma. Dig Dis Sci. 2012;57:1171–80.CrossRef
26.
Zhang W, Zhang T, Jin R, et al. MicroRNA-301a promotes migration and invasion by targeting TGFBR2 in human colorectal cancer. J Exp Clin Cancer Res. 2014;33:113.CrossRef
27.
Wang Y, Zhu YD, Gui Q, Wang XD, Zhu YX. Glucagon-induced angiogenesis and tumor growth through the HIF-1-VEGF-dependent pathway in hyperglycemic nude mice. Genet Mol Res. 2014;13:7173–83.CrossRef
28.
Lopez R, Arumugam A, Joseph R, et al. Hyperglycemia enhances the proliferation of non-tumorigenic and malignant mammary epithelial cells through increased leptin/IGF1R signaling and activation of AKT/mTOR. PLoS One. 2013;8:e79708.CrossRef
29.
Kapoor C, Vaidya S, Wadhwan V, Kaur G, Pathak A. Seesaw of matrix metalloproteinases (MMPs). J Cancer Res Ther. 2016;12:28–35.CrossRef
30.
Saengboonmee C, Seubwai W, Pairojkul C, Wongkham S. High glucose enhances progression of cholangiocarcinoma cells via STAT3 activation. Sci Rep. 2016;6:18995.CrossRef
31.
Li Y, Zhu W, Li J, Liu M, Wei M. Resveratrol suppresses the STAT3 signaling pathway and inhibits proliferation of high glucose-exposed HepG2 cells partly through SIRT1. Oncol Rep. 2013;30:2820–8.CrossRef
32.
Kang X, Kong F, Wu X, et al. High glucose promotes tumor invasion and increases metastasis-associated protein expression in human lung epithelial cells by upregulating heme oxygenase-1 via reactive oxygen species or the TGF-beta1/PI3K/Akt signaling pathway. Cell Physiol Biochem. 2015;35:1008–22.CrossRef
33.
Tsai JR, Wang HM, Liu PL, et al. High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients. Cell Oncol (Dordr). 2012;35:461–71.CrossRef
34.
Miyata Y, Kanda S, Mitsunari K, Asai A, Sakai H. Heme oxygenase-1 expression is associated with tumor aggressiveness and outcomes in patients with bladder cancer: a correlation with smoking intensity. Transl Res. 2014;164:468–76.CrossRef
35.
Alisson-Silva F, Freire-de-Lima L, Donadio JL, et al. Increase of O-glycosylated oncofetal fibronectin in high glucose-induced epithelial-mesenchymal transition of cultured human epithelial cells. PLoS One. 2013;8:e60471.CrossRef
36.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.CrossRef
37.
Viedma-Rodriguez R, Martinez-Hernandez MG, Flores-Lopez LA, Baiza-Gutman LA. Epsilon-aminocaproic acid prevents high glucose and insulin induced-invasiveness in MDA-MB-231 breast cancer cells, modulating the plasminogen activator system. Mol Cell Biochem. 2018;437:65–80.CrossRef
38.
Sun XF, Shao YB, Liu MG, et al. High-concentration glucose enhances invasion in invasive ductal breast carcinoma by promoting Glut1/MMP2/MMP9 axis expression. Oncol Lett. 2017;13:2989–95.CrossRef
39.
Li W, Ma Z, Ma J, et al. Hydrogen peroxide mediates hyperglycemia-induced invasive activity via ERK and p38 MAPK in human pancreatic cancer. Oncotarget. 2015;6:31119–33.PubMedPubMedCentral
40.
Cao L, Chen X, Xiao X, et al. Resveratrol inhibits hyperglycemia-driven ROS-induced invasion and migration of pancreatic cancer cells via suppression of the ERK and p38 MAPK signaling pathways [J]. Int J Oncol. 2016;49(2):735–43.CrossRef
41.
Rahn S, Zimmermann V, Viol F, et al. Diabetes as risk factor for pancreatic cancer: hyperglycemia promotes epithelial-mesenchymal-transition and stem cell properties in pancreatic ductal epithelial cells. Cancer Lett. 2018;415:129–50.CrossRef
42.
Takatani-Nakase T, Matsui C, Maeda S, et al. High glucose level promotes migration behavior of breast cancer cells through zinc and its transporters. PLoS One. 2014;9:e90136.CrossRef
43.
Garufi A, D'Orazi G. High glucose dephosphorylates serine 46 and inhibits p53 apoptotic activity. J Exp Clin Cancer Res. 2014;33:79.CrossRef
44.
D'Orazi G, Rinaldo C, Soddu S. Updates on HIPK2: a resourceful oncosuppressor for clearing cancer. J Exp Clin Cancer Res. 2012;31:63.CrossRef
45.
Baldari S, Garufi A, Granato M, et al. Hyperglycemia triggers HIPK2 protein degradation. Oncotarget. 2017;8:1190–203.CrossRef
46.
Jiang GM, Xie WY, Wang HS, et al. Curcumin combined with FAPalphac vaccine elicits effective antitumor response by targeting indolamine-2,3-dioxygenase and inhibiting EMT induced by TNF-αlpha in melanoma. Oncotarget. 2015;6:25932–42.PubMedPubMedCentral
47.
Guan J, Zhang H, Wen Z, et al. Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells. Cancer Lett. 2014;345:132–9.CrossRef
48.
Ma YS, Yang IP, Tsai HL, et al. High glucose modulates antiproliferative effect and cytotoxicity of 5-fluorouracil in human colon cancer cells. DNA Cell Biol. 2014;33:64–72.CrossRef
49.
Zhao W, Chen R, Zhao M, et al. High glucose promotes gastric cancer chemoresistance in vivo and in vitro. Mol Med Rep. 2015;12:843–50.CrossRef
50.
Biernacka KM, Uzoh CC, Zeng L, et al. Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2. Endocr Relat Cancer. 2013;20:741–51.CrossRef
51.
Al QA, Holly J, Perks C. Hypoxia negates hyperglycaemia-induced chemo-resistance in breast cancer cells: the role of insulin-like growth factor binding protein 2. Oncotarget. 2017;8:74635–48.
52.
Uzoh CC, Perks CM, Bahl A, et al. PTEN-mediated pathways and their association with treatment-resistant prostate cancer. BJU Int. 2009;104:556–61.CrossRef
53.
Zeng L, Biernacka KM, Holly JM, et al. Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. Endocr Relat Cancer. 2010;17:539–51.CrossRef
54.
Libby G, Donnelly LA, Donnan PT, et al, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2diabetes. Diabetes Care 2009;32(9):1620–1625. PubMed PMID: 19564453.CrossRef
55.
Zordoky BN, Bark D, Soltys CL, et al. The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention. Biochim Biophys Acta. 2014;1840:1943–57.CrossRef
56.
Takahashi A, Kimura F, Yamanaka A, et al. Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis. Cancer Cell Int. 2014;14:53.CrossRef
57.
Storozhuk Y, Hopmans SN, Sanli T, et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer. 2013;108:2021–32.CrossRef
58.
Li B, Takeda T, Tsuiji K, et al. The antidiabetic drug metformin inhibits uterine leiomyoma cell proliferation via an AMP-activated protein kinase signaling pathway. Gynecol Endocrinol. 2013;29:87–90.CrossRef
59.
Biernacka KM, Persad RA, Bahl A, et al. Hyperglycaemia-induced resistance to docetaxel is negated by metformin: a role for IGFBP-2. Endocr Relat Cancer. 2017;24:17–30.CrossRef
60.
Lee C, An D, Park J. Hyperglycemic memory in metabolism and cancer. Horm Mol Biol Clin Investig. 2016;26:77–85.PubMed
61.
Betancourt-Albrecht M, Cunningham GR. Hypogonadism and diabetes. Int J Impot Res. 2003;15(Suppl 4):S14–20.CrossRef
62.
Xu H, Zhang LM, Liu J, et al. The association between overall survival of prostate cancer patients and hypertension, hyperglycemia, and overweight in southern China: a prospective cohort study. J Cancer Res Clin Oncol. 2013;139:943–51.CrossRef
Metadata
Title
Effects of hyperglycemia on the progression of tumor diseases
Authors
Wenjie Li
Xuehui Zhang
Hui Sang
Ying Zhou
Chunyu Shang
Yongqing Wang
Hong Zhu
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2019
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-019-1309-6

Other articles of this Issue 1/2019

Journal of Experimental & Clinical Cancer Research 1/2019 Go to the issue

Research

PLEK2 promotes gallbladder cancer invasion and metastasis through EGFR/CCL2 pathway

Correction

Correction to: Targeted radiotherapy of pigmented melanoma with 131I-5-IPN

Research

MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma

Research

Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma

Research

Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells

Research

RETRACTED ARTICLE: A positive feedback loop consisting of C12orf59/NF-κB/CDH11 promotes gastric cancer invasion and metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits